Preclinical studies as well as phase I and II trials have demonstrated that SU11248 has
antitumor activity in renal cell carcinoma, breast cancer, neuroendocrine tumor and GIST. So
at the light of these pre-clinical and clinical data, it seems interesting and promising to
test SU011248 in these poor prognosis patients.
Phase:
Phase 2
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain